Zacks Investment Research
28 Oct 2026, 12:51 UTC · 1h ago
Boston Scientific (BSX) Q3 Earnings Match Estimates
Impact · against what's priced in
Boston Scientific's Q3 results are neutral as the modest revenue beat and EPS match align with a market that has already priced in decelerating growth and operational setbacks. The data confirms the company is operating within the lowered guidance expectations already absorbed by the stock price.
- BSX+0.00
Already priced in
- The price assumes
Revenue growth decelerating from the recent 19.9% pace down to roughly 6.7% annually
The reported year-over-year revenue increase of approximately 1.38% ($5.14 billion vs $5.07 billion) confirms the significant deceleration the market has already priced in.
What BSX's price assumes · Sep 10
Top 2 movers · tap to explore
